Virtual reality offers new hope for chronic pain sufferers

NCT ID NCT06964360

Completed Symptom relief Sponsor: Badalona Serveis Assistencials Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested a program called REDOCVR for 174 adults with chronic pain. The program combines group education, emotional support, and virtual reality experiences to help people reduce their pain medications. Researchers measured changes in medication use, mental well-being, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Virtual reality-enhanced psychoeducational program
What this could lead to: If it works, this could offer a way to reduce reliance on painkillers and improve quality of life for people with chronic pain.
What could go wrong: This is a completed early-stage trial with no phase designation, so results may not be conclusive. The program is complex and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL SENSITISATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome Emotional Regulation opiate dependence Patient Participation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL SENSITISATION CHRONIC PAIN OPIOID-RELATED DISORDERS PATIENT EMPOWERMENT

Contacts and locations

Locations

CAP Montgat- Dr Jardi

Montgat, Barcelona, Spain
Primary Care Center Apenins-Montigalà

Badalona, Barcelona, 08917, Spain
Primary Care Center Morera-Pomar

Badalona, Barcelona, Spain
Primary Care Progrès-Raval

Badalona, Barcelona, 08912, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.